Objective: To investigate whether i.v. injected corticotropin-releasing hormone (CRH) (1 mg/kg) has a direct effect on adipose tissue metabolism in humans. Design: Double-blinded, placebo-controlled, crossover study. Subjects: Twelve healthy normal weight female volunteers (age 20-37 years, body mass index: 22.7571.33 kg/m 2 ) Measurements: Assessment of local generation of glycerol, and glucose in adipose tissue by microdialysis. Measurement of adipose tissue and skin blood flow by laser Doppler flowmetry. Results: Injection of CRH acutely increases interstitial concentrations of glycerol (19.075.4%, Po0.05) and glucose (13.575.8%, Po0.05) reaching peak levels after 15 min. Plasma glycerol increases in parallel (D ¼ 16.775.9% after 15 min (Po0.05)), whereas plasma glucose remains unaffected. Changes in tissue blood flow do not explain interstitial metabolite alterations. Initial CRH effects on adipose tissue metabolism are short lasting and disappear after 15 min. Conclusions: The importance of CRH on human energy metabolism is underlined by the present in vivo study demonstrating peptidergic effects on lipolysis and glucose homeostasis in human subcutaneous adipose tissue.
Introduction
Hormones of the hypothalamic-pituitary-adrenal axis are critically involved in the regulation of appetite, energy expenditure and weight control. For example, cortisol excess causes weight gain and ultimately induces the metabolic syndrome. Species-specific metabolic effects of adrenocorticotropin hormone (ACTH) have been described, 1,2 and particularly corticotropin-releasing hormone (CRH) is a key hormone in weight regulation owing to its central nervous anorexogenic properties. It causes appetite suppression 3 and increases energy expenditure through sympathoexcitation 4 and acceleration of fat oxidation. 5, 6 Additionally, CRHstimulated ACTH secretion is positively correlated to body weight in humans. 7 In addition to its central nervous weight-regulating properties, CRH could also affect fat tissue metabolism by direct peptidergic mechanisms on the adipocyte. This is suggested by the presence of CRH receptors (CRH-R) in adipose tissue 8 where both subcutaneous and visceral compartments express CRH-R subtypes CRH-R1 and CRH-R2. 9 Furthermore, adipocytes themselves synthesize urocortin II and III, which both bind to CRH-R2 and regulate their expression through negative feedback mechanisms. However, whether and how CRH affects adipose tissue metabolism in vivo has never been examined in humans.
The aim of this study was to investigate the effect of i.v. CRH on lipolysis in subcutaneous white adipose tissue in humans. For this purpose, we monitored changes of interstitial glycerol and glucose in healthy female volunteers after injection of 1 mg/kg CRH in a crossover, placebo-controlled and double-blinded experimental design. As adipose tissue metabolism and interstitial metabolite concentration can also be influenced by changes in tissue perfusion, 10 laser Doppler flowmetry (LDF) was used to monitor adipose tissue blood flow (ATBF) during the experiments.
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Methods
Subjects
We recruited 12 female healthy volunteers with normal body weight. Exclusion criteria were a body mass index under 20 and over 25 kg m
À2
, any kind of medication, alcohol or nicotine abuse, any history of depression, sleep disorders, metabolic or endocrine illness and hypertension. Furthermore, all participants had to have a stable body weight for at least the 3 months before the experiment. All subjects were asked to refrain from excessive exercise for a period of 24 h before the experiments. A detailed history and a physical examination excluded current illness. The study was approved by the local ethics committee and all participants gave their written informed consent before the experiments.
Microdialysis
Microdialysis was performed using a high-precision pump (CMA 100, CMA Microdialysis, Solna, Sweden) and a commercially available microdialysis double lumen catheter (CMA 60, cutoff 20 000 Da), which was inserted via a guidance needle into the adipose tissue at the lateral aspect of the thigh. The flow rate was set to 2.5 ml/min. A washout and equilibration period of 60 min was allowed before the injection of placebo/CRH.
Laser doppler flowmetry
Changes in skin and ATBF were quantified by LDF using a two-channel Periflux system (Perimed 6005, Jårsfalla, Sweden). We could recently show that LDF provides a valuable and convenient tool to assess rapid perfusion changes in adipose tissue. 11 After a warm-up phase of 30 min, laser Doppler flow probes were calibrated with a motility standard. One probe (needle probe, Perimed) was then inserted at a 451 angle to insure measurement of ATBF 1 cm in depth next to the microdialysis probe and fixed to the skin with tape in order to minimize movement artifacts. A second laser Doppler probe (skin probe, Perimed) was attached to the skin 10 mm apart from tip of the needle probe to avoid interference.
Hemodynamic monitoring
Heart rate was recorded online using a three lead electrocardiogram (ECG) and breathing was monitored by a respiration transducer (Pneumotrace 1130, Adinstruments, Spechbach, Germany). Finger blood pressure (BP) was measured continuously using the volume clamp method throughout the whole experiment (Finapres, Ohmeda 2600, Engelwood, CO, USA) and calibrated versus oscillometric BP measured on the contralateral arm (Welch Allyn, Skaneateles Falls, NY, USA). ECG, continuous blood pressure curves, respiration and LDF signals were registered online with a multi-channel analogue/digital converter (Powerlab sp16, Adinstruments, Spechbach, Germany) at a sampling rate of 200/s. Blood pressure was calculated as 1-min averages of peak systolic and diastolic measurements; LDF curves were analyzed calculating area under the curve in 1-min intervals.
Protocol
The study followed a balanced, randomized, double-blinded crossover protocol and subjects received either CRH 1 mg/kg (CRH, Ferring, Kiel, Germany) or placebo (5 ml 0.9% saline) i.v. The interval between both experimental sessions was 2 weeks.
Subjects arrived at the research unit at 08:00hours after an overnight fast. After emptying their bladder, they rested comfortably in a supine position with the upper body slightly (301) elevated. A 16 G venous cannula (Becton Dickinson GmbH, Heidelberg, Germany) was inserted into the cubital vein for blood sampling. Microdialysis, LDF and hemodynamic monitoring were prepared and then the equilibration period for the microdialysis probe was started. After 60 min, equilibration experiments began with a 30 min baseline period during which microdialysis and blood samples were collected at intervals of 15 min. Then the study drug (1 ml isotonic saline or 1 mg/kg CRH in 1 ml solvent containing saline and hydrochloric acid with a pH of 2.75) was injected. Thereafter, dialysate samples were collected in 5 min intervals during the first 15 min after injection and subsequently in 10 min intervals until the end of the experiment. Blood for analysis of ACTH, cortisol, plasma glycerol and glucose was sampled every 10 min during the first hour and in 30 min intervals, thereafter. The experiment was finished 120 min after drug injection. All blood samples were immediately centrifuged and stored at À801 until further analysis.
Biochemistry
Glycerol and glucose in dialysate and plasma were analyzed using a colorimetric enzymatic method in a CMA/600 analyzer (CMA Microdialysis, Sweden). Baseline values were set to 100% and all following data were expressed as percentage from baseline. Concentrations of plasma-free fatty acids were measured with an enzymatic method (Biotrol, Paris, France). Serum cortisol was determined by radioimmunoassay (DPC Biermann GmbH, Bad Nauheim, Germany). Plasma ACTH was determined by immunoluminometric assay (Lumitest, Brahms, Berlin, Germany). The interassay coefficient of variation for the ACTH and cortisol assay was below 10%. All samples were analyzed in duplicate in the same assay.
Data of blood pressure, heart rate, skin and adipose tissue perfusion was analyzed off-line using the CHART software (CHART 5, Adinstruments, Spechbach, Germany).
CRH
Statistical evaluation
Statistical analysis relied on analysis of variance (ANOVA) with repeated measures factor 'time' and the group factor 'treatment' (GraphPad Prism version 4.00 for Windows, GraphPad Software, San Diego, CA, USA). When ANOVA showed significant treatment effects, subsequent post hoc pairwise comparisons were performed. A Greenhouse Geissercorrected P-value of o0.05 was considered significant. Results are presented as mean7s.e.m.
Results
Injection of 1 mg/kg CRH was well tolerated by all volunteers. Three subjects reported a transient feeling of abdominal discomfort and five participants experienced flush-like symptoms after CRH i.v. As expected, injection of CRH caused a strong increase of ACTH from 9.571.5 pg/ml at baseline to a secretory maximum of 26.872.8 pg/ml after 45 min (Po0.001 for 'time' and 'treatment'). Likewise, cortisol increased from 7.670.94 to 19.171.0 mg/dl after 60 min (Po0.001 for 'time' and 'treatment').
Metabolites CRH had an acute and clear effect on interstitial subcutaneous adipose tissue concentrations of glucose and glycerol (Figure 1 ), whereas injection of placebo had no effect on these parameters. Interestingly, glucose concentrations were increased biphasically, a first peak of 19.075.5% from baseline (Po0.05) occurred after 15 min. Subsequently, interstitial glucose levels fell back to baseline after 20 min. Thereafter, glucose concentration rose again, approaching a second peak with a maximum difference from baseline of 34.2077.75% after 90 min (Po0.001). Plasma glucose of the venous blood, however, remained unchanged throughout the experiment.
Interstitial glycerol concentrations in adipose tissue increased by 20.274.4% 15 min after injection of CRH (Po0.05 for 'treatment'). Thereafter, glycerol concentration fell and reached baseline levels 30 min after CRH injection. Plasma glycerol levels rose by 16.875.9% reaching peak levels after 15 min (Figure 1 ). This increase persisted longer than in the interstitium remaining elevated until 45 min after CRH injection. Free fatty acids in plasma increased 15 min after CRH reaching a maximum D 15.674.6% from baseline after 30 min (Figure 2 ).
Blood flow
Skin blood flow increased transiently after CRH injection showing a maximum peak after 10 min (Po0.05) and remained slightly above baseline values afterwards, showing no significant difference to the placebo group, however. ATBF was not affected by CRH but increased independently from treatment over the whole experimental period in most subjects (Po0.05 for factor 'time'). CRH and adipose tissue metabolism P Wellhöner et al
Discussion
The present study defines several new aspects regarding the importance of CRH for human energy metabolism. I.v. injection of CRH evoked an immediate increase in interstitial concentrations of glycerol and glucose in the femoral adipose tissue of female subjects. It also had acute short lasting effects on blood flow and caused an increase in erythrocyte flux, which, however, was restricted to the epidermal layer of the skin. The change in cutaneous blood flow, however, cannot explain the observed metabolic alterations induced by CRH because they were restricted to the skin. By using an additional subcutaneous LDF probe to monitor blood flow changes within the adipose tissue, we were able to exclude any CRH effect on microcirculation in the fat tissue compartment. Thus, changes in interstitial metabolite concentrations can be attributed to a specific peptidergic effect of CRH on lipolysis and glucose metabolism in human adipose tissue. Glycerol, in contrast to fatty acids, is metabolized to a negligible extent by adipose tissue. 12 Therefore, the rise in interstitial glycerol levels in our study can be interpreted as stimulated lipolysis. 13 Our in vivo data do not confirm results of in vitro studies where CRH caused a decrease of glycerol in the culture medium of human adipocytes. 14 The increase in interstitial glycerol was paralleled by a similar increase in plasma glycerol and free fatty acids, which persisted for 45 min. The persisting elevation of plasma glycerol levels suggests that the short lasting increase in interstitial glycerol contributes to the increase in plasma glycerol and is not secondarily caused by glycerol diffusion from the plasma to the interstitial space. Adipose tissue is the major source for plasma glycerol; 15 however, subcutaneous and visceral adipose tissue differs in terms of CRH-R subtypes. Although subcutaneous fat cells express more CRH-R1, CRH-R2 predominate in visceral adipose tissue. 9 Hence, CRH may have even stronger and more sustaining effects on metabolically more active fat tissues like the visceral fat depots, which may explain the prolongation of glycerol and free fatty acids elevation in plasma. The immediate metabolic response suggests a direct CRH-R-mediated effect on adipocytes. However, we cannot exclude that fat tissue lipolysis is also affected by other hormones of the hypophyseal adrenocortical axis, which are secreted in response to CRH like, for example, ACTH, which has been reported to cause lipolysis in rodent adipose tissue. 1 In humans, however, administration of ACTH failed to cause lipolysis 2 and hence casts doubt on the hypothesis that the peptide has enough lipolytic strength to explain the glycerol increase in our experiment. Cortisol, on the other hand, also has well-known effects on fat tissue metabolism. Djurhuus et al. 16, 17 could demonstrate that a constant infusion of hydrocortisone causes significant lipolysis in adipose tissue, which became significant after 240 min. This time course of corticosteroid-induced lipolysis argues against the hypothesis that the CRH-induced cortisol increase had evoked the lipolysis observed in our experiment. An unexpected finding of the present study is the biphasic CRH effect on interstitial glucose concentration with an early elevation immediately after injection and a second more prolonged elevation, which became significant after 45 min. This increase in interstitial glucose was not accompanied by any elevation of plasma glucose that excludes that the rise in interstitial glucose is a consequence of an increased hepatic gluconeogenesis or caused by any other effect on systemic glucose levels. It is intriguing to speculate whether the observed increase of interstitial glucose derives from the adipose tissue itself. There have been reports about extrahepatic glucose production in the kidneys, 18 but to the best of our knowledge, adipose tissue possesses no capability of gluconeogenesis or glucose secretion. ATBF was similar in both conditions, which excludes any differences caused by an altered tissue perfusion. That CRH induces local accumulation of glucose in the adipose tissue could be explained by a reduced glucose uptake by the fat cells. However, to our knowledge, there is no data regarding a direct effect of CRH on glucose transport, like it has been shown for steroids in in vitro studies. 19 In our experiments, the increase in interstitial glucose concentration was possibly too small to be detected in the blood because the peripheral fat tissue contributes only minimally to the whole-body glucose homeostasis in the postabsorbtive state as it accounts only for approximately 8% of total body glucose uptake. 20 For the interpretation of the metabolic changes of our study, it is important to consider that we report relative changes in interstitial metabolite concentrations. The reason for this approach is the fact that a high dialysate flow rate is needed to obtain a sufficient probe volume of at least 10 ml within 5 min to detect acute peptidergic effects. However, such high flow rate shortens the diffusion time of the metabolite. In consequence, only a proportion of the interstitial metabolites diffuse into the dialysate. Additionally, metabolite dialysate concentrations depend on the recovery of the microdialysis membrane that is unlikely to be CRH and adipose tissue metabolism P Wellhöner et al identical between different catheters. Therefore, absolute metabolite concentrations are difficult to obtain with the present experimental approach and we chose to restrict our analysis of metabolic CRH effects on relative changes in metabolite concentration. Another restriction of our study is that the microdialysis catheters only allowed the passage of relatively small molecules. It is possible that CRH induced alterations in the paracrine system of the adipose tissue, which can be better characterized by microperfusion methods. 21 In summary, our study underlines the importance of CRH for human subcutaneous fat tissue metabolism. It not only increases lipolysis but is also involved in local glucose homeostasis. These effects could be explained by direct peripheral peptidergic effects on adipocytes.
